MICHAEL S VAJDY

Summary

Affiliation: Chiron Corporation
Country: USA

Publications

  1. ncbi Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry
    M Vajdy
    Vaccines Research, Chiron Corporation, 4560 Horton Street, M S 4 3, Emeryville, CA 94604, USA
    Curr Drug Targets Immune Endocr Metabol Disord 3:222-33. 2003
  2. ncbi Generation and maintenance of mucosal memory B cell responses?
    M Vajdy
    Novartis Vaccines and Diagnostics, Inc, 4560 Horton Street, M S 4 3 Emeryville, CA 94608, USA
    Curr Med Chem 13:3023-37. 2006
  3. ncbi Current efforts on generation of optimal immune responses against HIV through mucosal immunisations
    Michael Vajdy
    Novartis Vaccines and Diagnostics, Emeryville, California 94608, USA
    Drugs R D 7:267-88. 2006
  4. ncbi Intranasal delivery of vaccines against HIV
    Michael Vajdy
    Chiron Vaccines, 4560 Horton Street, Emeryville, CA 94608, USA
    Expert Opin Drug Deliv 3:247-59. 2006
  5. ncbi The role of adjuvants in the development of mucosal vaccines
    Michael Vajdy
    Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608, USA
    Expert Opin Biol Ther 5:953-65. 2005
  6. ncbi Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations
    Michael Vajdy
    Chiron Corporation, Vaccine Research, Emeryville, California 94608, USA
    AIDS Res Hum Retroviruses 20:1269-81. 2004
  7. ncbi Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines
    Michael Vajdy
    Chiron Vaccines, Emeryville, California 94608, USA
    Immunol Cell Biol 82:617-27. 2004
  8. pmc Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery
    Amanda Goodsell
    Novartis Vaccines and Diagnostics, Inc, Emeryville, CA 94608, USA
    Immunology 123:378-89. 2008
  9. pmc Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and no
    Yinling Lin
    Novartis Vaccine and Diagnostic, Inc, Emeryville, California 94608, USA
    J Virol 82:7492-503. 2008
  10. pmc Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant
    Fengmin Zhou
    Novartis Vaccines and Diagnostics, Inc, Emeryville, California, USA
    Clin Vaccine Immunol 16:471-8. 2009

Research Grants

  1. Alphavirus Replicons for Mucosal HIV Vaccines
    Michael Vajdy; Fiscal Year: 2002

Detail Information

Publications24

  1. ncbi Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry
    M Vajdy
    Vaccines Research, Chiron Corporation, 4560 Horton Street, M S 4 3, Emeryville, CA 94604, USA
    Curr Drug Targets Immune Endocr Metabol Disord 3:222-33. 2003
    ..Furthermore, a summary of current and future therapeutic treatment targets will be presented...
  2. ncbi Generation and maintenance of mucosal memory B cell responses?
    M Vajdy
    Novartis Vaccines and Diagnostics, Inc, 4560 Horton Street, M S 4 3 Emeryville, CA 94608, USA
    Curr Med Chem 13:3023-37. 2006
    ..This review deals with the concept of mucosal B cell memory with special emphasis on efforts to devise effective prophylactic or therapeutic vaccines...
  3. ncbi Current efforts on generation of optimal immune responses against HIV through mucosal immunisations
    Michael Vajdy
    Novartis Vaccines and Diagnostics, Emeryville, California 94608, USA
    Drugs R D 7:267-88. 2006
    ..This review discusses current efforts on the generation of optimal immune responses against HIV in the genitourinary and intestinal tracts using mucosal immunisations alone or combinations of mucosal and parenteral immunisations...
  4. ncbi Intranasal delivery of vaccines against HIV
    Michael Vajdy
    Chiron Vaccines, 4560 Horton Street, Emeryville, CA 94608, USA
    Expert Opin Drug Deliv 3:247-59. 2006
    ....
  5. ncbi The role of adjuvants in the development of mucosal vaccines
    Michael Vajdy
    Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608, USA
    Expert Opin Biol Ther 5:953-65. 2005
    ..The paper will conclude with the authors' opinion on how the field will or should progress in the future and what will be the required components of ideal future mucosal vaccines that can induce immunological memory...
  6. ncbi Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations
    Michael Vajdy
    Chiron Corporation, Vaccine Research, Emeryville, California 94608, USA
    AIDS Res Hum Retroviruses 20:1269-81. 2004
    ....
  7. ncbi Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines
    Michael Vajdy
    Chiron Vaccines, Emeryville, California 94608, USA
    Immunol Cell Biol 82:617-27. 2004
    ....
  8. pmc Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery
    Amanda Goodsell
    Novartis Vaccines and Diagnostics, Inc, Emeryville, CA 94608, USA
    Immunology 123:378-89. 2008
    ..These data show for the first time that mucosal followed by systemic immunizations with gene delivery systems enhance B-cell responses independent of the mucosal homing receptors alpha4beta7 and alphaEbeta7...
  9. pmc Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and no
    Yinling Lin
    Novartis Vaccine and Diagnostic, Inc, Emeryville, California 94608, USA
    J Virol 82:7492-503. 2008
    ..This vaccine formulation and regimen may therefore be optimal in humans for protection against this highly heterogeneous global pathogen...
  10. pmc Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant
    Fengmin Zhou
    Novartis Vaccines and Diagnostics, Inc, Emeryville, California, USA
    Clin Vaccine Immunol 16:471-8. 2009
    ..5 months after the second immunization...
  11. pmc Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant
    Susan W Barnett
    Novartis Vaccines and Diagnostics, 350 Massachusetts Avenue, Cambridge, MA 02139, USA
    J Virol 84:5975-85. 2010
    ....
  12. doi Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope
    Susan W Barnett
    Novartis Vaccines and Diagnostics, Inc, 4560 Horton Street, Emeryville, California 94608, USA
    AIDS 22:339-48. 2008
    ..Worldwide, the majority of human immunodeficiency virus (HIV) infections occur by heterosexual transmission. Thus, the development of a vaccine that can prevent intravaginal HIV infection is an important goal of AIDS vaccine research...
  13. ncbi Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses
    Michael Vajdy
    Chiron Vaccines, Emeryville, CA 94608, USA
    J Gen Virol 87:2253-62. 2006
    ..These data suggest that the HCV polyprotein delivered with adjuvants induces broad B- and T-cell responses and could be a vaccine candidate against HCV...
  14. doi Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes
    Indresh Srivastava
    Novartis Vaccines and Diagnostics, Inc, 4560 Horton Street, M S 4 3, Emeryville, CA 94563, USA
    Vaccine 26:2796-806. 2008
    ..Thus, depending on the immunization intervals, IN/IM may be more effective than IM immunizations for short- and long-term immunity...
  15. ncbi Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant
    Elawati Soenawan
    Chiron Corporation, Immunology and Infectious Diseases, Emeryville, CA, USA
    Vaccine 22:1553-63. 2004
    ..Following oral immunizations, in the persistent/resting memory phase, hapten-specific IgM titers in serum and IgM-SC in bone marrow (BM) dominated the immune response, suggesting an important role for IgM in the maintenance of memory...
  16. pmc Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations
    Michael Vajdy
    Immunology and Infectious Diseases, Emeryville, CA, USA
    Immunology 110:86-94. 2003
    ..n. recall immunization is required to induce both mucosal and systemic memory type responses...
  17. ncbi A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza
    Michael Vajdy
    Novartis Vaccines and Diagnostics, Inc, Emeryville, CA 94608, USA
    Clin Immunol 123:166-75. 2007
    ....
  18. ncbi A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge
    Catherine E Greer
    Vaccines Research, Chiron Corporation, 4560 Horton Street, MS 4 3, Emeryville, CA 94608, USA
    Vaccine 25:481-9. 2007
    ..These data suggest that the alphavirus replicon platform can be useful for a PIV3 vaccine and possibly other respiratory viruses...
  19. pmc An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector
    Silvia Perri
    Vaccine Research, Chiron Corporation, Emeryville, California 94608, USA
    J Virol 77:10394-403. 2003
    ..This work shows that combining desirable elements from VEE and SIN into a replicon particle chimera may be a valuable approach toward the goal of developing vaccine vectors with optimal in vivo potency, ease of production, and safety...
  20. pmc Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes
    Mingke Yu
    EpitoGenesis, Inc, Walnut Creek, CA 94598, USA
    Expert Opin Biol Ther 10:1181-95. 2010
    ..An effective vaccine that can induce both systemic and local mucosal immunity is generally accepted as a major means of protection against mucosal HIV transmission and AIDS...
  21. ncbi A comparison of anionic nanoparticles and microparticles as vaccine delivery systems
    Janet Wendorf
    Novartis Vaccines and Diagnostics, Inc, Emeryville, CA 94608, USA
    Hum Vaccin 4:44-9. 2008
    ..For the gp140, the LTK63 was necessary for high titers. Both nanoparticles and microparticles are promising delivery systems...
  22. pmc Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate
    Indresh K Srivastava
    Vaccines Research, Chiron Corporation, Emeryville, California 94608, USA
    J Virol 77:11244-59. 2003
    ..e., SF162. These results highlight a potential role for the trimeric o-gp140SF162DeltaV2 Env immunogen in a successful HIV vaccine...
  23. pmc Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008
    ..These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels...
  24. ncbi The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles
    Padma Malyala
    Novartis Vaccines and Diagnostics, 4560 Horton St, M S 4 355, Emeryville, CA 94608, USA
    J Pharm Sci 97:1155-64. 2008
    ..Encapsulating CpG within PLG microparticles induced statistically significant higher antibody, bactericidal activity and T cell responses when compared to the traditional method of delivering CpG in the soluble form...

Research Grants1

  1. Alphavirus Replicons for Mucosal HIV Vaccines
    Michael Vajdy; Fiscal Year: 2002
    ....